Lumos Pharma (previously NewLink Genetics) is developing vaccines based on the its proprietary HyperAcute® vaccine technology, which involves α(1,3)-galactosyltransferase (αGal) gene modification of vaccines, including virus-like particle vaccines and recombinant vaccines. The αGal gene codes for an enzyme that adds certain sugars to proteins and lipids in the cell membranes of lower mammals. Humans do not express these sugar moieties and therefore develop a strong immunological response to cells expressing these modifications. αGal-modification of vaccines enhances immune responses without the use of an adjuvant. NewLink Genetics has investigated the feasibility of αGal of various influenza vaccines, but the company has stated that the HyperAcute® vaccine technology is not limited to influenza vaccines. Preclinical development is underway in the US.
Lumos Pharma is also developing a Zika vaccine candidate for the treatment of Zirus virus infections  .
As at August 2018, no recent reports of development had been identified for preclinical development in Influenza-virus-infections (Prevention) in USA (Parenteral).
As at March 2020, no recent reports of development had been identified for research development in Zika-virus-infection in USA (Parenteral).
In March 2020, NewLink Genetics Corporation and Lumos Pharma merged to form Lumos Pharma  .
Key Development Milestones
In February 2016, NewLink Genetics initiated a Zika vaccine programme to develop a vaccine candidate for the treatment of Zika virus infection  .
A presentation on the efficacy of αGal-modified influenza vaccines was made at the XVth International Congress of Virology in July 2014  .